Compare Enveric Biosciences Inc (ENVB) vs NRG Energy Inc (NRG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs NRG Energy Inc — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.80M), while NRG Energy Inc trades at $106.74 (market cap $22.35B). The key difference: NRG Energy Inc is far larger — about 3286.8× Enveric Biosciences Inc's market cap, and NRG Energy Inc pays a 1.79% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and NRG Energy Inc for 62 Days on average.
| ENVB | NRG | |
|---|---|---|
Market Cap | $6.80M | $22.35B |
Volume | 64,867 | 5,011,942 |
Sector | Health | Utilities |
52-Week High | $10.80 | $184.03 |
52-Week Low | $1.27 | $95.23 |
Typical Hold Time | 14 Days | 62 Days |
Enterprise Value | -$1.49M | $46.30B |
Dividend Yield | — | 1.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
NRG Energy trades at $108.61, up 4.84% with bullish technical signals and strong analyst support. The stock shows robust fundamentals with $30.71B revenue, 2.56% net margin, and attractive valuation at P/E 28.28 and P/S 0.66. Recent developments include a transformative 1.2 GW Texas data center power project and LS Power acquisition driving growth. Cash flow trends improved significantly from 2023's negative $1.5B to 2025's positive $3.83B, though 2026 projects a temporary dip.
Outlook remains positive with 70% analyst buy ratings and $202.90 consensus target representing 87% upside. Key opportunities include data center expansion and customer-backed power projects, while risks involve elevated debt levels (56.42% debt-to-asset ratio) and recent earnings misses. The stock presents growth potential but requires monitoring of execution on major capital projects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About NRG Energy Inc
NRG Energy is one of the largest retail energy providers in the U.S., with 7 million customers, including its 2021 acquisition of Direct Energy. It also is one of the largest U.S. independent power producers, with 16 gigawatts of nuclear, coal, gas, and oil power generation capacity primarily in Texas. Since 2018, NRG has divested its 47% stake in NRG Yield, among other renewable energy and conventional generation investments. NRG exited Chapter 11 bankruptcy as a stand-alone entity in December 2003.
Read more on NRG →
